CLA-2-29:OT:RR:NC:N1:138
Ms. Sheila Heerdt
Ren Pharm International Ltd.
350 Jericho Turnpike, Suite 204
Jericho, NY 11753
RE: The tariff classification of Ixazomib (CAS No. 1072833-77-2) in bulk powder form, from Taiwan
Dear Ms. Heerdt:
In your letter dated November 21, 2017, you requested a tariff classification ruling.
The subject product, Ixazomib, is a proteasome inhibitor that is indicated in combination with other drugs for the treatment of multiple myeloma, which is a type of white blood cell cancer.
The applicable subheading for the Ixazomib in bulk powder form will be 2931.90.2200, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Other organo-inorganic compounds: Other: Aromatic: Other: Drugs.” The rate of duty will be 6.5 percent ad valorem. Currently, Ixazomib is not listed in the Pharmaceutical Appendix to the Tariff Schedule.
Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on World Wide Web at https://hts.usitc.gov/current.
This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov.
This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177).
A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Judy Lee at [email protected].
Sincerely,
Steven A. Mack
Director
National Commodity Specialist Division